{"preliminary_commentary":{"by_channel":{"x_thread":19,"podcast":3,"youtube":2},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04579380\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"drugs_tested":[["tucatinib","trastuzumab"],["tucatinib","trastuzumab","fulvestrant"]],"indication":"previously treated advanced solid tumors with HER2 alterations","name":"SGNTUC-019","nct_id":"NCT04579380","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=sgntuc-019-nct04579380. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Tucatinib + trastuzumab (+ fulvestrant in hormone-receptor positive HER2-mutant breast cancer only)","label":"Tucatinib + Trastuzumab (+ Fulvestrant)","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2026-12-31","type":"ESTIMATED"},"conditions":["Uterine Neoplasms","Uterine Cervical Neoplasms","Biliary Tract Neoplasms","Urologic Neoplasms","Carcinoma, Non-Small-Cell Lung","HER2 Mutations Breast Neoplasms"],"enrollment":{"count":217,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"tucatinib","otherNames":["TUKYSA, ARRY-380, ONT-380"],"type":"DRUG"},{"name":"trastuzumab","otherNames":["Herceptin"],"type":"DRUG"},{"name":"fulvestrant","otherNames":["Faslodex"],"type":"DRUG"}],"last_update":"2026-08-21","lead_sponsor":"Seagen, a wholly owned subsidiary of Pfizer","official_title":"A Phase 2 Basket Study of Tucatinib in Combination With Trastuzumab in Subjects With Previously Treated, Locally Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2023-11-01","type":"ACTUAL"},"primary_outcomes":[{"measure":"Confirmed Objective Response Rate (cORR) as Assessed by Investigator","timeFrame":"From the first dose of study treatment until the first documented CR or PR on or before the first documented PD or new anti-cancer therapies or death, whichever occurred first (up to 28.3 months)"}],"references":[{"citation":"Okines AFC, Curigliano G, Mizuno N, Oh DY, Rorive A, Soliman H, Takahashi S, Bekaii-Saab T, Burkard ME, Chung KY, Debruyne PR, Fox JR, Gambardella V, Gil-Martin M, Hamilton EP, Monk BJ, Nakamura Y, Nguyen D, O'Malley DM, Olawaiye AB, Pothuri B, Reck M, Sudo K, Sunakawa Y, Van Marcke C, Yu EY, Ramos J, Tan S, Bieda M, Stinchcombe TE, Pohlmann PR. Tucatinib and trastuzumab in HER2-mutated metastatic breast cancer: a phase 2 basket trial. Nat Med. 2025 Mar;31(3):909-916. doi: 10.1038/s41591-024-03462-0. Epub 2025 Jan 17.","pmid":"39825152","type":"DERIVED"},{"citation":"Nakamura Y, Mizuno N, Sunakawa Y, Canon JL, Galsky MD, Hamilton E, Hayashi H, Jerusalem G, Kim ST, Lee KW, Kankeu Fonkoua LA, Monk BJ, Nguyen D, Oh DY, Okines A, O'Malley DM, Pohlmann P, Reck M, Shin SJ, Sudo K, Takahashi S, Van Marcke C, Yu EY, Groisberg R, Ramos J, Tan S, Stinchcombe TE, Bekaii-Saab T. Tucatinib and Trastuzumab for Previously Treated Human Epidermal Growth Factor Receptor 2-Positive Metastatic Biliary Tract Cancer (SGNTUC-019): A Phase II Basket Study. J Clin Oncol. 2023 Dec 20;41(36):5569-5578. doi: 10.1200/JCO.23.00606. Epub 2023 Sep 26.","pmid":"37751561","type":"DERIVED"}],"start_date":{"date":"2021-01-11","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations","url":"https://clinicaltrials.gov/study/NCT04579380"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/sgntuc-019-nct04579380"}